501 Shares in Eli Lilly and Company $LLY Bought by Shah Wealth Advisors LLC

Shah Wealth Advisors LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 501 shares of the company’s stock, valued at approximately $580,000.

Other large investors have also modified their holdings of the company. Wellington Grp LLC boosted its stake in shares of Eli Lilly and Company by 2.5% in the third quarter. Wellington Grp LLC now owns 13,305 shares of the company’s stock valued at $15,395,000 after buying an additional 326 shares in the last quarter. Addison Advisors LLC grew its holdings in Eli Lilly and Company by 4.0% during the third quarter. Addison Advisors LLC now owns 284 shares of the company’s stock worth $328,000 after acquiring an additional 11 shares during the period. Bernicke Wealth Management Ltd. acquired a new position in Eli Lilly and Company during the third quarter worth $5,001,000. Vista Capital Partners Inc. purchased a new position in Eli Lilly and Company in the third quarter worth $1,276,000. Finally, McElhenny Sheffield Capital Management LLC raised its position in Eli Lilly and Company by 8.3% in the third quarter. McElhenny Sheffield Capital Management LLC now owns 469 shares of the company’s stock worth $543,000 after acquiring an additional 36 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LLY. TD Cowen reissued a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,650.00 price target on shares of Eli Lilly and Company in a research note on Friday, October 30th. Royal Bank Of Canada lifted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a report on Friday, October 30th. Sanford C. Bernstein reissued an “outperform” rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a research report on Monday, October 26th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,416.64.

Check Out Our Latest Stock Analysis on LLY

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Up 0.0%

Shares of LLY opened at $1,444.05 on Monday. The firm has a market cap of $1.36 trillion, a PE ratio of 46.87, a price-to-earnings-growth ratio of 1.73 and a beta of 0.40. The company’s fifty day moving average is $1,242.25 and its two-hundred day moving average is $1,110.30. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,460.00. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same period in the previous year, the company earned $7.02 EPS. Analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.